Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
NCT03179995 · Fox Chase Cancer Center · PHASE2 · terminated · last registry update 2024-02-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Grantor closed study” | – | Registry record, Fox Chase Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SSTR5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-02-06Results posted on the registry: University of Utah, a drug against SSTR5 (NCT05680675)
- 2025-02-04Phase 3 first posted: SWOG Cancer Research Network, Lanreotide (NCT06807437)
- 2025-01-31Also stopped (withdrawn): Jules Bordet Institute, 225Ac-DOTATATE (NCT06411301)
- 2025-01-24Results posted on the registry: Advanced Accelerator Applications, arginine/lysine (NCT04524442)
- 2025-01-20Phase 3 first posted: Novartis Pharmaceuticals, Octreotide LAR (NCT06784752)
- 2025-01-13Also stopped (terminated): Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Capecitabine + Lu-PRRT (NCT02736448)
- 2025-01-13Also stopped (terminated): Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, 177Lu-DOTATATE 25.9 GBq activity + 177Lu-DOTATATE 18.5 GBq activity (NCT02489604)
- 2024-11-27Results posted on the registry: Advanced Accelerator Applications, Lutetium [177Lu] oxodotreotide/dotatate (NCT04711135)
- 2024-10-26Also stopped (withdrawn): University of Chicago, Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT) (NCT05610826)
- 2024-10-10Results posted on the registry: Advanced Accelerator Applications, Lutathera + 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot) (NCT03972488)
- 2024-10-01Results posted on the registry: Ipsen, Lanreotide autogel (NCT04852679)
- 2024-09-25Phase 3 first posted: University Hospital, Grenoble, 68Ga-DOTATOC (NCT06611891)
- 2024-08-28Results posted on the registry: RECORDATI GROUP, Pasireotide + Cabergoline (NCT01794793)
- 2024-07-24Results posted on the registry: Columbia University, Sandostatin LAR (NCT01424241)
- 2024-07-10Also stopped (withdrawn): Columbia University, Insulin human + Octreotide Acetate (NCT06126354)
- 2024-05-03Phase 3 first posted: Sinotau Pharmaceutical Group, Lutetium[177Lu] Oxodotreotide Injection (NCT06398444)
- 2024-04-29Also stopped (withdrawn): David Bushnell, Lutathera + Azedra (NCT04614766)
- 2024-03-06Also stopped (withdrawn): University of California, Los Angeles, Angiotensin II + Midodrine (NCT04048707)
- 2024-03-05Results posted on the registry: Dana-Farber Cancer Institute, Ramucirumab + Somatostatin Analog (NCT02795858)
- 2024-02-08Also stopped (terminated): Gustave Roussy, Cancer Campus, Grand Paris, Pasireotide 0.9 MG/ML (NCT04826432)
- 2023-12-05Also stopped (terminated): SCRI Development Innovations, LLC, Lanreotide (NCT02859064)
- 2023-11-28Also stopped (terminated): Sandeep Laroia, [90]Y-DOTATOC (NCT03724409)
- 2023-10-19Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., 68Ga-DOTATOC (NCT06091748)
- 2023-10-02Phase 3 first posted: National Hepatology & Tropical Medicine Research Institute, PPI group + PPI plus octreotide (NCT06062719)
- 2023-07-27Results posted on the registry: SCRI Development Innovations, LLC, Lanreotide (NCT02859064)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision